ReviewHuman vaccines & immunotherapeutics2022
The biophysical principles underpinning muco-trapping functions of antibodies.
Review in Human vaccines & immunotherapeutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 25 citations in OpenAlex.
- Mucins and Respiratory Virus Infection.Annual review of virology · 2026Review
- Vectored Immunoprophylaxis for Mucosal Immunity: Advances and Challenges Associated with Recombinant Secretory IgA Expression.Vaccines · 2026Review
- An Inverse Transwell Assay for Airway Mucus Barrier Function Reveals both Virus- and Mucin-Specific Impacts on Infection.bioRxiv : the preprint server for biology · 2026Article
- Synthetic mucus biomaterials enable localized therapeutic antibody delivery in inflammatory bowel disease.APL bioengineering · 2026Article
- Topology Determines DNA Origami Diffusion in Intestinal Mucus.Nano letters · 2025Article
- Inhaled biologics for respiratory diseases: clinical potential and emerging technologies.Drug delivery and translational research · 2025Review
- Engineering Decavalent, Sperm-Binding Laminin-IgG Hybrid Antibodies for Potent Non-Hormonal Contraception.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- An Effective Oral Nanodelivery Material for Curcumin: Ingenious Utilization of Gastrointestinal Absorption Characteristics.Molecules (Basel, Switzerland) · 2025Article
- Rotavirus-specific neutralization assay enables evaluation of mucosal immune responses.Frontiers in immunology · 2025Article
- The forecasting power of the mucin-microbiome interplay in livestock respiratory diseases.The veterinary quarterly · 2024Article
- Review
- Tethering of soluble immune effectors to mucin and chitin reflects a convergent and dynamic role in gut immunity.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2024Review
- Different Forms of TFF3 in the Human Endocervix, including a Complex with IgG Fc Binding Protein (FCGBP), and Further Aspects of the Cervico-Vaginal Innate Immune Barrier.International journal of molecular sciences · 2024Article
- Antibody protection from SARS-CoV-2 respiratory tract exposure and infection.Journal of theoretical biology · 2023Article
- Innovations in monoclonal antibody-based multipurpose prevention technology (MPT) for the prevention of sexually transmitted infections and unintended pregnancy.Frontiers in reproductive health · 2023Review
- Article
- Therapeutic antibodies - natural and pathological barriers and strategies to overcome them.Pharmacology & therapeutics · 2022Review
- Special focus issue: passive immunization.Human vaccines & immunotherapeutics · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
In addition to the classical immunological functions such as neutralization, antibody-dependent cellular cytotoxicity, and complement activation, IgG antibodies possess a little-recognized and under-utilized effector function at mucosal surfaces: trapping pathogens in mucus. IgG can potently immobilize pathogens that otherwise readily diffuse or actively swim through mucus by forming multiple low-affinity bonds between the array of pathogen-bound antibodies and the mucin mesh. Trapping in mucus can exclude pathogens from contacting target cells, and facilitate their rapid elimination by natural mucus clearance mechanisms. Despite the fact that most infections are transmitted at mucosal surfaces, this muco-trapping effector function has only been revealed within the past decade, with the evidence to date suggesting that it is a universal effector function of IgG-Fc capable of immobilizing both viral and highly motile bacterial pathogens in all major mucosal secretions. This review provides an overview of the current evidence for Fc-mucin crosslinking as an effector function for antibodies in mucus, the mechanism by which the accumulation of weak Fc-mucin bonds by IgG bound to the surface of a pathogen can result in immobilization of antibody-pathogen complexes, and how trapping in mucus can contribute to protection against foreign pathogens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.